Cargando…

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer

Antitumor immunity is an essential component of cancer therapy and is primarily mediated by the innate immune response, which plays a critical role in initiating and shaping the adaptive immune response. Emerging evidence has identified innate immune checkpoints and pattern recognition receptors, su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Rui, Chu, Xiaohong, Zhang, Jibing, Fu, Rongrong, Feng, Changshun, Jia, Dianlong, Wang, Rui, Yan, Hui, Li, Guangyong, Li, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095745/ https://www.ncbi.nlm.nih.gov/pubmed/37049910 http://dx.doi.org/10.3390/molecules28073147

Ejemplares similares

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

Anticancer Effect of STING Agonist-Encapsulated Liposomes on Breast Cancer
por: Zhang, Jibing, et al.
Publicado: (2023)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
por: Jalil, AbdelAziz R, et al.
Publicado: (2020)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2022)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
por: Andrechak, Jason C., et al.
Publicado: (2022)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
por: Hendriks, Mark A. J. M., et al.
Publicado: (2020)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy
por: Xie, Zhongjian, et al.
Publicado: (2020)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis
por: Li, Yiqing, et al.
Publicado: (2023)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer
por: Ji, Kai, et al.
Publicado: (2023)

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
por: Cabrales, Pedro
Publicado: (2019)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
por: Qu, Tailong, et al.
Publicado: (2022)

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
por: Hutter, Gregor, et al.
Publicado: (2019)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
por: Wang, Sean K., et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8mknrpge2udmug9nphbnla17vh